1065 East Hillsdale Boulevard
Foster City, CA 94404
650 525 5535
Impiegati a tempo pieno: 46
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Senthil Vel Sundaram||CEO & Director||994,65k||N/D||1978|
|Dr. Erin Quirk M.D.||Pres & Head of R&D||808,16k||N/D||1971|
|Mr. Seokho Yoon Esq.||COO, Gen. Counsel & Sec.||712,84k||N/D||1978|
|Dr. Weidong Zhong Ph.D.||Co-Founder & Exec. Officer||N/D||N/D||1966|
|Dr. Mark Joseph Vignola||CFO & Treasurer||N/D||N/D||1978|
|Dr. Jeffrey R. Jasper Ph.D.||Sr. VP & Head of Research||N/D||N/D||N/D|
|Ms. Diana Chung||Sr. VP & Chief Devel. Officer||N/D||N/D||N/D|
|Dr. Kerry Russell M.D., Ph.D.||Chief Medical Officer of Metabolic||N/D||N/D||N/D|
|Dr. Emil T. Kuriakose M.D.||Chief Medical Officer of Oncology||N/D||N/D||1980|
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
L'ISS Governance QualityScore di Terns Pharmaceuticals, Inc. al 1 giugno 2023 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 8; retribuzione: 8.